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ABSTRACT
Patients receiving immunosuppressive drugs to prevent organ transplant rejection exhibit a greatly
increased risk of developing cutaneous squamous cell carcinoma (SCC). However, not all immunosup-
pressive drugs confer the same risk. Randomised, controlled trials demonstrate that switching renal
transplant recipients receiving calcineurin inhibitor-based therapies to mammalian target of rapamycin
(mTOR) inhibitors results in a reduced incidence of de novo SSC formation, and can even result in the
regression of pre-existing premalignant lesions. However, the contribution played by residual immune
function in this setting is unclear. We examined the hypotheses that mTOR inhibitors promote the
enhanced differentiation and function of CD8+ memory T cells in the skin. Here, we demonstrate that
the long-term oral administration of rapamycin to achieve clinically-relevant whole blood drug target
thresholds, creates a “low rapamycin dose” environment in the skin. While both rapamycin and the
calcineurin inhibitor tacrolimus elongated the survival of OVA-expressing skin grafts, and inhibited short-
term antigen-specific CD8+ T cell responses, rapamycin but not tacrolimus permitted the statistically
significant infiltration of CD8+ effector memory T cells into UV-induced SCC lesions. Furthermore,
rapamycin uniquely enhanced the number and function of CD8+ effector and central memory T cells
in a model of long-term contact hypersensitivity provided that rapamycin was present during the
antigen sensitization phase. Thus, our findings suggest that patients switched to mTOR inhibitor regi-
mens likely experience enhanced CD8+ memory T cell function to new antigen-challenges in their skin,
which could contribute to their lower risk of de novo SSC formation and regression of pre-existing
premalignant lesions.
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Introduction
Renal transplant recipients often receive triple therapy with
combinations of Glucocorticoids (prednisolone or prednisone),
calcineurin inhibitors (cyclosporine or tacrolimus) and anti-pro-
liferative agents (azathioprine or mycophenolic acid) to prevent
rejection of their allografts.1,2 Worldwide, these patients suffer a
65–250 fold increased risk of non-melanoma skin cancer (NMSC;
primarily basal cell carcinoma and squamous cell carcinoma,
SCC) development compared with the general population.3,4 A
single follow-up study of renal transplant recipients in
Queensland reported increased NMSC incidence with increasing
duration of immunosuppression, with over 50% developing at
least one tumour within 10 years of starting immunosuppressive
therapy.3 Some renal transplant patients currently presenting to
the Princess Alexandra Hospital, Brisbane, Australia require the
removal of ~120 primary skin tumors each year. Metastatic SCC,
and not organ failure or rejection, is now the leading cause of
death in renal transplant patients in Australia.5
Despite receiving triple therapy, the substitution of a single
agent (i.e. a calcineurin inhibitor for a mTOR inhibitor) has been
shown to reduce de novo SSC formation,6–9 induce regression of
pre-existing premalignant lesions,8 and in at least 3 separate
clinical studies lead to 100% tumour regression of cutaneous
Kaposi’s sarcoma lesions in kidney transplant recipients, with no
apparent loss of graft function.10–12 However, conversion from
calcineurin inhibitors to mTOR inhibitors is frequently associated
with a significant increase in adverse events, including oedema,
diarrhoea, headache, mouth ulceration, pneumonitis, and
impaired wound healing that ultimately combine to result in a
high degree of drug discontinuation.6–8,13–15 Nevertheless, there is
substantial benefit associated with conversion tomTOR inhibitors
in terms of the anti-neoplastic effect on SCC.
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The direct effects of calcineurin inhibitors and mTOR
inhibitors on tumour growth and survival have been exten-
sively studied in the laboratory, with a general consensus that
calcineurin inhibitors are pro-neoplastic while mTOR inhibi-
tors are anti-neoplastic.1 However, patients treated topically
with the calcineurin inhibitor tacrolimus for moderate to
severe atopic dermatitis do not display an increased risk of
SCC formation.16–18 This argues against a pro-neoplastic
effect of calcineurin inhibitors in the skin solely due to direct
transformation events. Similarly, at least 2 independent clin-
ical studies have reported that the use of high doses of the
mTOR inhibitor sirolimus (also known as rapamycin) abolish
the anti-tumour effects shown by low doses of sirolimus,
leading to Kaposi sarcoma development and/or recurrence.-
19,20 Recently, the long-term administration of the mTOR
inhibitor everolimus to patients was shown to correlate with
an increase in the production of Eomesodermin+ memory
CD8+ T-cells.21 These observations cast doubt on the assump-
tion that the anti-neoplastic effects of mTOR inhibitors rest
solely on direct tumour growth inhibition. Together, these
studies may suggest a role for residual immune function in
the differential effects of calcineurin inhibitors and mTOR
inhibitors on SCC growth and survival. The effects that
these inhibitors have on the function of immune cells within
SCC however, remain largely unstudied.
In mice, treatment with low doses (75µg/kg; blood levels;
5–20 ng/ml) of the mTOR inhibitor rapamycin following
acute lymphocytic choriomeningitis virus infection was
described to enhance not only the quantity but also the quality
of virus-specific memory CD8+ T cells.22 Mechanistically, low
dose rapamycin treatment increased the number of memory
precursor cells during the T cell expansion phase, which
resulted in an accelerated memory T cell differentiation pro-
gram (effector to memory transition) during the T cell con-
traction phase.22 These effects were not seen when high doses
(600µg/kg; blood levels; 40–100 ng/ml) of rapamycin were
used when, conversely, T cell responses during the expansion
phase were inhibited. The impact of low dose rapamycin may
be linked to the importance of cellular metabolism in deter-
mining T cell differentiation; a pathway heavily regulated by
mTOR.23 mTOR inhibition facilitates the transition of highly
metabolic effector cells into a more catabolic state required for
memory cell differentiation in response to mitogenic and
growth factor withdrawal.24 mTOR inhibition, but not calci-
neurin inhibition, has been shown to produce memory CD8+
T cell precursors that demonstrate enhanced subsistence and
antigen-recall responses upon adoptive transfer.25
Importantly, low dose mTOR inhibition produces little inter-
ference with effector molecules such as IFN-γ, perforin, or
granzyme B, leading to the suggestion that anti-tumour T cell
responses might be permitted in patients treated with mTOR
inhibitors.26
We recently examined the abundance of multiple T cell
subsets in the skin of kidney transplant patients receiving
either rapamycin (sirolimus)- or calcineurin inhibitor-based
drug therapy, and demonstrated that sirolimus treatment, but
not calcineurin inhibitor treatment, led to significant increases
in the abundance of CD8+ memory T cells in sun-exposed
skin as compared to non-sun exposed skin in intrapatient
analyses.27 CD8+ T cells play a critical protective role in the
body by recognizing and destroying virally-infected- and
malignant cells,28–33 and by influencing other immune cell
populations through the production of Th1-biased cytokines
including IFN-γ.34,35 We have shown previously that SCC
lesions specifically display a lower abundance of CD8+ T
cells than premalignant lesions in immune-competent
patients.36 Given this link between mTOR inhibitor use and
CD8+ memory T cell abundance in patient skin, we examined
the role of clinically-relevant rapamycin concentrations in the
differentiation and function of CD8+ memory T cells in SCC
and the skin.
Materials and methods
Mice
All animal procedures were approved by the University of
Queensland Animal Ethics Committee; Approval Numbers 342/
11 and 466/14. C57BL/6J mice were purchased from the Animal
Resources Facility Perth, Australia. K5mOVAmice, which express
membrane-bound OVA in the skin under the control of the K5
promoter,37 K14HPV38 E6/E7mice, which express the E6 and E7
genes of Human Papillomavirus (HPV) type 38 under the control
of the Keratin 14 promoter,38 OT-II mice, and B6.SJL (CD45.1+) x
OT-I, and Nzeg (GFP+) x OT-I mice carrying a MHC class
I-restricted transgenic TCR for the OVA257–264 (SIINFEKL) pep-
tide were bred and maintained locally at the Translational
Research Institute Biological Research Facility (Brisbane,
Australia). All mice used were 6–12 wk females and were housed
under specific pathogen-free conditions.
Antibodies and reagents
OVA257–264 (SIINFEKL) peptide was purchased fromProimmune
Ltd (Oxford, UK). Ovalbumin (OVA), bovine serum albumin
(BSA), phytohemagglutinin (PHA), zinc sulphate, saponin and
2,4-dinitrofluorobenzene (DNFB) were purchased from Sigma-
Aldrich (St. Louis, MO). Acetonitrile, Titrisol buffer, and tert-
butyl methyl ether (TBME) were purchased from Merck KGaA
(Darmstadt, Germany). Tacrolimus and rapamycin were pur-
chased from LC Laboratories (Woburn, MA). Flow-Count
Fluorospheres were purchased from Beckman Coulter (Miami,
FL, USA) and carboxyfluorescein diacetate succinimidyl ester
(CFSE), CellTrace Violet (CTV), Live/Dead Fixable Aqua Dead
Cell Stain, and anti-CD3/CD28 Dynabeads were purchased from
Thermo Fisher Scientific (Waltham, MA, USA). Purified 53–5.8
(anti-CD8β-depleting antibody) and anti-HRPN isotype control
was purchased from BioXCell (West Lebanon, NH, USA).
Brefeldin A, FITC-conjugated H57-597 (anti-TCRβ), APC-con-
jugated 53–6.7 (anti-CD8α), 53–5.8 (anti-CD8β.2), XMG1.2 (anti-
IFN-γ), 145-2C11 (anti-CD3ԑ), andH1.2F3 (anti-CD69), PE-con-
jugated MEL-14 (anti-CD62L), B20.1 (anti-TCRVα2), and 4C7
(anti-CD207), PE/Dazzle-conjugated 16-10A1 (anti-CD80),
AX647-conjugated MF-14 (anti-FoxP3), AX488-conjugated
HM40-3 (anti-CD40), PE-Cy7-conjugated RI7217 (anti-CD71),
A20 (anti-CD45.1), GK1.5 (anti-CD4), N418 (anti-CD11c),
H1.2F3 (anti-CD69) and 53–6.7 (anti-CD8α), PerCP-Cy5.5-con-
jugated 104 (anti-CD45.2) and 145-2C11 (anti-CD3ԑ) and H57-
597 (anti-TCRβ), APC-Cy7-conjugated IM7 (anti-CD44) and
e1479627-2 J.-W. JUNG ET AL.
M5/114.15.2 (anti-I-A/I-E), BV605-conjugated 53–6.7 (anti-
CD8α), BV650-conjugated M1/70 (anti-CD11b), BV785-conju-
gated MP6-XT22 (anti-TNFα) and GL-1 (anti-CD86), and
BV421-conjugated 2E7 (anti-CD103) were purchased from
Biolegend (San Diego, CA, USA) or eBioscience (San Diego,
CA, USA). Collagenase D, Dispase II, and DNase 1 were pur-
chased from Roche (Indianapolis, IN, USA). Ascomycin – the
internal standard for tacrolimus – was supplied by Fujisawa
Pharmaceutical Company (Osaka, Japan). 32-O-desmethoxyrapa-
mycin – the internal standard for rapamycin – was supplied by
Wyeth-Ayerst Research (Princeton, NJ, USA).
Dendritic cell isolation from skin
Ears and inguinal lymph nodes were harvested from mice
recipient of control or drug diets for 22 days. On the day
prior to harvest the mice received an injection containing
25µg of CpG and 25µg of Poly I:C s.c. near the inguinal
lymph nodes. Ears were split into dorsal and ventral halves
using forceps and excess collagen removed by scraping with a
sharp blade. Ear halves were then placed dermis-side down in
RPMI media containing 2.5mg/ml Dispase II for 60 minutes
at 37°C to allow separation of epidermal sheets using forceps.
Epidermal and dermal tissue was placed into separate tubes,
cut into small fragments, and digested for 45 minutes (epi-
dermis) or 60 minutes (dermis) at 37°C with 1 mg/ml col-
lagenase D and 20 ug/ml Dnase 1. Tissues were then passed
through a 70 μm cell strainer (BD Biosciences, San Jose, CA)
to create a single-cell suspension.
T cell isolation from skin and AK/SCC lesions
To release cells from ear skin, back skin, and AK/SCC lesions
for analysis by flow cytometry, harvested tissue was cut into
small fragments and digested for 1 hour at 37°C with 1 mg/ml
collagenase D and 20 ug/ml Dnase 1. Tissues were then passed
through a 70 μm cell strainer (BD Biosciences, San Jose, CA)
to create a single-cell suspension.
Phenotypic and functional analysis of cell populations by
flow cytometry
Isolated cells were resuspended in PBS/0.5% FBS and incu-
bated with Fc-block and 2% rat serum for 20 minutes on ice
to block non-specific antibody staining. Intracellular staining
for Foxp3 and CD207 (lymph nodes and dermis only) was
performed using the Foxp3/Transcription Factor Staining
Buffer Set Kit (eBioscience) according to the manufacturers’
instructions. Monoclonal antibodies for surface staining were
subsequently added for 30 minutes on ice in concert with
Live/Dead Aqua Stain to elucidate live cell populations.
Immediately before FACS acquisition, Flow-Count
Fluorospheres were added to allow assessment of total cell
counts. For analysis of intracellular cytokine production, bone
marrow-derived dendritic cells (generated as described pre-
viously using IL-4 and GMCSF 39 (cytokines from R&D
Systems, Minneapolis, MN) were pulsed with 100µg/ml
OVA or BSA protein for 4 hours, and then 10,000 cells were
co-cultured with each ear homogenate sample for 16.5 hours
at 37°C. 5µg/ml Brefeldin A was added for the last 4.5 hours
of culture, and intracellular staining performed as described
previously.40 LSR II, FACSCanto, or LSR Fontessa (BD
Biosciences, San Jose, CA) Flow Cytometers were used for
FACS analysis, and Kaluza (Beckman Coulter, Orange
County, CA) and FlowJo (TreeStar Inc., Ashland, OR) soft-
wares were used for data analysis.
Diet-based drug delivery
All customised mice diet was manufactured by Specialty Feeds
(Perth, WA). Briefly, tacrolimus or rapamycin was mixed with
caster sugar and then incorporated into standard mouse diet.
1.5 g of tacrolimus or 1.0 g of rapamycin was mixed with
100 g of caster sugar and 9.9 kg of standard mouse diet to
result in tacrolimus-diet or rapamycin-diet respectively. Food
colouring was added to distinguish drug types. During the
manufacturing process the pellets were air-dried overnight
rather than dried in an oven in order to minimise the amount
of heat applied. The final product was sealed in airtight bags
and stored at 4°C protected from light to ensure minimal
degradation. Pellet volumes in feed hoppers were kept to a
minimum and restocked every 3–4 days for the duration of
the experiments.
Quantification of drug concentrations in blood and tissues
Blood. Blood was collected in EDTA, immediately mixed to
prevent coagulation, and stored at −20°C. For consistency,
samples were collected at the same time each day (12 noon).
25 µl of the blood samples were transferred into a 96-well
round bottom 2 ml polypropylene deep well plate (Axygen
Scientific, Union City, CA). After addition of 100 µl 0.1 M
zinc sulphate into each well, the plate was vortexed for 10
secs. 250 µl of HPLC-grade acetonitrile containing 5 µg/L
internal standard (ascomycin or 32-O-desmethoxyrapamycin)
was added per well, vortexed for 2 mins, and centrifuged for
3 mins at 800g. 20 – 40 µl of the supernatant was then
analysed using LC-MS/MS (Alliance HT LC system interfaced
to a Quattro Micro tandem mass spectrometer (Waters
Corporation, Milford, MA) or Quattro-Premier mass spectro-
meter (Waters Corporation) was used for measurements of
tacrolimus or rapamycin respectively. Calibration standards
and quality control samples were prepared in human blood
using independent stock drug solutions. The mass transitions
monitored for tacrolimus were m/z 821.3 → 768.3 and m/z
809.3 → 756.3 for the internal standard (ascomycin), with a
dwell time of 150 ms, and the mass transitions monitored for
rapamycin were m/z 931.3 → 864.2 and m/z 901.3 → 834.2
for the internal standard (32-O-desmethoxyrapamycin), with
a dwell time of 100 ms.
Skin. 4 cm2 of skin/mouse was carefully excised and sub-
cutaneous tissues removed. Tissue samples were weighed, cut
into small pieces, and then placed into a tissue grinding tube
(Precellys® Lysing Kit; MK28-R; Bertin Technologies,
Montigny-le-Bretonneux, France) containing 1 ml of Titrisol
buffer and 60 µl of internal standard (ascomycin or 32-O-
desmethoxyrapamycin). Rapamycin (0, 2, 5, 10, 50 ng/ml) and
tacrolimus (0, 1, 5, 20, 50 ng/ml) standards were prepared in
50% methanol/MilliQ H2O, and then diluted in Titrisol buffer
concentrate pH 10 to give a final concentration of 0, 0.2, 0.5,
1.0, 5.0 and 10.0 ng/ml for rapamycin and 0, 0.1, 0.5, 2.0 and
5.0 ng/ml for tacrolimus. Standard curves were prepared using
skin of untreated mice and the addition of 1 ml of
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reconstituted standards and 60 µl of internal standard.
Samples were homogenised using a using a Precellys® 24
Homogenizer (Bertin Technologies) at 6500 rpm, 30 seconds
for 5 cycles, with the tubes placed on ice for at least 1 min
between each cycle to prevent drug degradation. The homo-
genised contents were then transferred into 10 ml screw top
glass tubes and 5ml of TBME added to each. The liquid-liquid
extraction process was performed manually by inverting the
tubes for at least 5 mins. Tubes were then centrifuged at room
temperature at 1800g for 3 mins to separate all the layers, and
the TBME containing the partitioned drug was transferred
into a new 5 ml glass tube. The TBME was evaporated using
a Sample Concentrator (Techne Dri-Block, DB-3D,
Cambridge, England) at 35°C and the residue subsequently
reconstituted with 200 µl 50% methanol by vortexing thor-
oughly. Reconstituted samples were transferred into UPLC
max recovery sample vials (Waters Corporation) and analysed
using LC-MS/MS as described above.
Kidney. Drug quantification in the kidney was performed
using the same protocol described in the skin assay. Kidneys
were not perfused prior to harvest. Standards were prepared
using drugs added to kidneys from untreated mice, to give a
final concentration of 0, 2.0, 5.0, 10.0, 20.0 and 40.0 ng/ml for
rapamycin and 0, 0.5, 2.0, 5.0, 10.0 and 20.0 ng/ml for
tacrolimus.
Analysis of immunosuppression in vitro
Naïve splenocytes harvested from B6.SJL x OT-I mice were
analysed for their ability to proliferate in the presence or
absence of tacrolimus or rapamycin in response to co-culture
with 0.1 µg/ml SIINFEKL peptide, anti-CD3/CD28 beads (at a
cells to beads ratio of 2:1) or 10 µg/ml PHA. Cells were
labelled with 2 µM CFSE, plated in triplicate wells, and co-
cultured with SIINFEKL, anti-CD3/CD28 beads, or PHA,
with or without the indicated concentration of tacrolimus or
rapamycin, for 72 hrs at 37°C. Cells were then stained with
anti-CD8β, and analysed by flow cytometry. The proliferation
index (PI) was calculated as previously described.41
Analysis of immunosuppression in vivo
Splenocytes and lymph node cells were harvested from naive
B6.SJL x OT-I, Nzeg x OT-I, or OT-II mice, labelled with
2 µM CFSE or 5 µM CTV, and intravenously injected (1x107
cells) into C57BL/6 recipient mice treated with either drug-
incorporated diet or daily drug i.p. injection as indicated.
OVA (50 µg) or BSA (50 µg) was injected s.c. near both
inguinal lymph nodes on Day 3. Inguinal lymph nodes were
harvested on Day 6, stained with the relevant antibodies, and
analysed via flow cytometry.
UV-induction of SCC
The backs of K14 HPV38 E6/E7 mice were shaved and
exposed to UV light 3 times per week using UV bulbs pur-
chased from Vilber Lourmat (model T-40M, 40 Watts, Marne
La Vellee, France) and emitting peak UV irradiation in the
UV-B spectrum (312 nm). Polyvinyl chloride (PVC) was used
to filter out UVC light. The dose of UV started at 120 mJ/cm2
on Week 1, and was gradually increased to 450 mJ/cm2 by
Week 20, and thereafter maintained at 450 mJ/cm2, as
described previously.38 CD8+ T cell subset identification and
quantification was as described above.
Analysis of T cell function in the skin
Skin grafting. Ears were collected from donor C57BL/6 and K5m.
OVA mice and separated into dorsal and ventral sides using
forceps. Dorsal C57BL/6 (surgical control) and dorsal K5m.
OVA (test) ear skin was then grafted side-by-side onto the thor-
acic flank region of an anesthetized C57BL/6 recipient. Grafts
were held in place with antibiotic-permeated gauze (Bactigras;
Smith and Nephew, London, U.K.) and bandaged with micropore
tape (Micropore TM: 3M Health Care, Minnesota, U.S.) and an
elastic bandage (3M Vetrap Bandaging TAPE, Vet n Pet Direct,
Queensland, Australia). After 7 days, bandages were removed and
grafts were photographed three times a week. For experiments
examining CD8+ T cell depletion, mice were immunised with
either 100µg of anti-CD8β or 100µg of anti-HRPN isotype control
i.p. on day 0, followed by 50µg injections on days 7, 10, and 35. For
experiments examining the effect of drugs, mice were fed a drug-
containing diet for 14 days before grafting and throughout the
remainder of the experiment. Graft rejectionwas assessed by a loss
of distinct border and signs of shrinkage, ulceration and/or necro-
sis to >80% of the graft area. Mice in which the control C57BL/6
graft did not heal were not included in final analyses.
Contact hypersensitivity (CHS). Mice were sensitized by a single
s.c. injection into the flank skin containing 100 µg OVA + 20 µg
saponin in 200 µl of PBS (Day 0). Five days (short-term CHS
response) or 45 (memory CHS response) days later, mice were
challenged with OVA (15 µg OVA in 10 µl PBS, i.d.) in the right
ear, and PBS (10 µl PBS, i.d.) in the left ear. Ear thicknesses were
measured after 24 and 48 hours using a dial thickness gauge
(Peacock, Model G-1A; Ozaki, Tokyo, Japan), and the increase
in ear swelling was determined as the percentage difference in ear
thickness between the OVA-treated versus the PBS-treated ears of
the same mouse. To achieve CD8+ T cell depletion, 10 µg of anti-
CD8β antibody was injected i.p on Days −7, −4, −1, and 3 (short-
termCHS), or onDays 33, 36, 39, and 43 (memory CHS). CD8+ T
cell depletion in the blood was assessed on Day 0 (short-term
CHS), or on Day 40 (memory CHS), by FACS analysis, and was
found to consistently result in at least 99.7% reduction in total
CD8+ T cell numbers. CD8+ T cell numbers in the ear skin were
determined as described above 8 days following antigen challenge
when ear swelling was judged to have completely subsided.
Statistical analysis
All statistical analysis was carried out using GraphPad Prism
version 6.02 or 7.03 (GraphPad Software, San Diego, CA,
USA). Statistical tests are as indicated in figure legends. A P
value of p < 0.05 (*) was considered significant. p < 0.01 (**),
p < 0.001 (***), and p < 0.0001 (****) are indicated.
Results
Establishment of drug diets to deliver clinically-relevant
in vivo drug concentration profiles
Immunosuppressant drugs are administered orally to trans-
plant patients ensuring consistent and predictable long-term
drug delivery. In order to deliver rapamycin or tacrolimus
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orally to mice over prolonged time-periods, we established
customised drug-incorporated mouse diets. Before the incor-
poration of the drugs into the diets we confirmed the ability
of rapamycin and tacrolimus to suppress CD8+ T cell prolif-
eration in vitro. Splenocytes from OT-I transgenic mice were
labelled with CFSE and stimulated in the presence or absence
of rapamycin (Supplementary Figure 1A) or tacrolimus
(Supplementary Figure 1B). SIINFEKL peptide, anti-CD3/
CD28 beads, or phytohemagglutinin (PHA) were used to
assess CD8+ T cell proliferation in response to antigen-speci-
fic stimulation, TCR/co-stimulatory-dependent stimulation,
or mitogen-stimulation respectively. The Proliferation Index
of CD8+ T cells was calculated based on CFSE-dilution 41 and
observed to be significantly reduced when cells were treated
with rapamycin or tacrolimus in all stimulation conditions.
Rapamycin or tacrolimus was then incorporated into standard
mouse diet, which was stored in vacuum-sealed bags in the dark at
4°C in order to counteract the loss of drug with time and ensure
predictable drug-delivery. To confirm that clinically-relevant drug
thresholds were being established following the administration of
customised drug-diets, LC-MS/MS analysis was performed on
unfractionated whole mouse blood over time. As shown in
Supplementary Figure 1C, mice fed the rapamycin-diet eventually
established a plateau blood concentration between 15- and 22 ng/
ml, which is within the clinical target range (10 – 30 ng/ml).42
Mice fed tacrolimus-diet achieved blood concentrations of tacro-
limus between 3 – and 9 ng/ml, which is on the lower end of the
clinical target range (5 – 20 ng/ml 43Supplementary Figure 1D),
however we chose not to increase the dose of tacrolimus due to an
associated increase in complications following experiments invol-
ving surgical skin-grafting procedures. Mice were weighed each
week and were found to demonstrate a slight reduction in weight
gain when compared with mice fed a control diet (Supplementary
Figure 1E), but were otherwise healthy and active. The customised
drug diets therefore, provided a means to deliver rapamycin and
tacrolimus to mice in a physiologically relevant manner and
maintain clinically-relevant drug concentrations in the blood
over a prolonged period of time.
Clinically-relevant rapamycin concentrations have little
impact on the abundance of epidermal and dermal
dendritic cells, or the abundance of CD8+ T cells in the
skin draining lymph nodes
To examine the consequence of clinically-relevant concentra-
tions of rapamycin on immune cell abundance in the skin and
skin-draining lymph nodes, we analysed dendritic cell (DC)
subsets in the epidermis and dermis, and DC and T cell
subsets in the skin draining lymph nodes. In the epidermis,
numbers of CD207+(Langerin+)MHC-II+CD11c+ Langerhans
cells (LCs) were not significantly altered by rapamycin-diet or
tacrolimus-diet compared with the control (No Drug) group
(Figure 1A). In the dermis, the frequencies of DC subsets,
including Langerin+CD103+ dermal DC (dDC) and
Langerin+CD103− transmigrating LCs, also appeared unaf-
fected by either drug diet (Figure 1B). To determine the
frequency of DC and T cells subsets in the skin-draining
lymph nodes, we mechanically disrupted pairs of inguinal
lymph nodes and performed FACS analyses of single cell
suspensions. As shown in (Figure 1C), neither rapamycin
nor tacrolimus had a significant impact on the abundance of
MHC-II+CD11c+CD8α+ lymph node-resident DC.
Tacrolimus but not rapamycin however, reduced the absolute
number of MHC-II+CD11c+CD11b+ lymph node-resident
DC. Rapamycin, by contrast, slightly increased the proportion
of CD11b+ DC within the MHC-II+CD11c+ DC compart-
ment. Interestingly, while neither rapamycin nor tacrolimus
significantly reduced the number of CD8α−CD11b−
Langerin+CD103+ dDC or CD8α−CD11b− Langerin+CD103−
transmigrating LCs, both drugs reduced the number of
CD103−CD207− DC (Figure 1D). To examine the impact of
clinically-relevant rapamycin concentrations on the activation
of lymph node DC, we injected CpG/Poly I:C s.c near the
inguinal lymph nodes 24 hours before lymph node harvest,
however no significant differences in the expression of CD86,
CD80, or CD40 activation markers by lymph node DC subsets
were detected between drug-treated and control groups (data
not shown).
Overall, and in contrast to tacrolimus-diet, rapamycin-diet did
not lead to a significant reduction in the total number of cells or
the number of CD8+ T cells in the skin-draining lymph nodes
(Figure 1E). Both rapamycin-diet and tacrolimus-diet however,
led to a reduction in the absolute number of CD4+ T cells and
FoxP3+CD4+ regulatory T cells within the skin-draining lymph
nodes (Figure 1E), although the effects of tacrolimus-diet were
more pronounced. Tacrolimus-diet, but not rapamycin-diet, also
reduced the proportion of FoxP3+CD4+ regulatory T cells within
the total CD4+ T cell pool (Figure 1E). Our attempts to similarly
assess CD4+ T cell and FoxP3+CD4+ regulatory T cell abundance
within the dermis were unsuccessful due to the cleavage of CD4
expression by dispase II treatment, which is needed to separate the
epidermis from the dermis. Taken together, and with the excep-
tion of lymph node CD103−CD207− DC, we observed that the
abundance of CD8+ T cells in the skin-draining lymph nodes, and
the abundance of DC subsets in the epidermis, dermis, and skin-
draining lymph nodes, was similar when mice recipient of clini-
cally-relevant concentrations of rapamycin were compared to
control mice.
Clinically-relevant rapamycin concentrations induce CD8+
T cell suppression in the skin-draining lymph nodes
In order to assess whether clinically-relevant rapamycin concen-
trations attained functional CD8+ T cell suppression in the skin-
draining lymph nodes, we introduced CFSE-labelled CD45.1+
OT-I lymphocytes into C57BL/6 recipient mice being treated
with either drug-incorporated diet or daily i.p. drug injection.
Three days later mice received Ovalbumin (OVA; 50 µg) or
Bovine Serum Albumin (BSA; as a control; 50 µg) injected s.c.
near the inguinal lymph nodes, and a further three days later the
inguinal lymph nodes were harvested and analysed for CFSE-
dilution in CD45.1+CD3ԑ+CD8α+ cells by flow cytometry (see
Supplementary Figure 2A for representative FACS plots). CD8+
T cell proliferation was found to be suppressed following the
administration of rapamycin-diet to a level similar to that sup-
pressed by the daily i.p injection of 2mg/kg rapamycin
(Figure 2A), similar to 600µg/kg rapamycin; Supplementary
Figure 2B. Similarly, tacrolimus-diet suppressed CD8+ T cell
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Figure 1. Clinically relevant doses of rapamycin do not impact DC numbers in the skin nor CD8+ T cell numbers in skin draining lymph nodes. (A-B) FACS
analysis of DC in the epidermis (A) and dermis (B) of enzymatically digested ear skin from naïve mice (No Drug), or mice fed rapamycin-diet (RAPA) or tacrolimus-diet
(TAC) for 22 days. Populations in plots are gated on Live CD45+ cells (A) and Live CD45+MHC II+CD11c+ cells (B). Numbers and percentages in bar graphs indicate
mean absolute counts within analysed tissues or percentage of cells in the respective gate or quadrant ± SEM. (C-E) FACS analysis of DC (C-D) or Total/T cells (E) in
pooled inguinal lymph node pairs from the same mice as A-B. Populations in plots are gated on Live MHC II+CD11c+ cells (C), Live MHC II+CD11c+CD8α−CD11b− cells
(D), and Live TCRβ+ cells ± CD8α, CD4, and/or FoxP3 (E). Numbers and percentages in bar graphs indicate mean absolute counts within paired inguinal lymph nodes
or percentage of cells in the respective gate or quadrant ± SEM. Data were combined from 2 independent experiments with similar results. n = 6 mice/group. (A, B,
and E) One-way ANOVA with post-hoc Tukey’s multiple comparisons test. (C-D) Two-way ANOVA with post-hoc Tukey’s multiple comparisons test.
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proliferation to a level similar to that suppressed by the daily i.p.
injection of 10mg/kg tacrolimus (Figure 2B). LC-MS/MS analysis
of the blood taken the day before lymphocyte transfer showed that
(at the time of sampling) the rapamycin-diet and rapamycin
injections had established similar rapamycin concentrations in
the blood (Figure 2C). However, a similar analysis of the two
tacrolimus-delivery methods revealed that tacrolimus-diet had
established higher tacrolimus concentrations in the blood than
tacrolimus injection (Figure 2D). In contrast to the reduced pro-
liferative capacity shown by CD8+ T cells in skin-draining lymph
nodes, the proliferative capacity of CD4+ OT-II T cells did not
appear to be significantly impacted by our rapamycin- and tacro-
limus-diets (Figure 2E). Together, these data indicate that both
rapamycin-diet and tacrolimus-diet induced systemic CD8+ T
cell, but not CD4+ T cell, suppression in vivo.
Clinically-relevant rapamycin concentrations induce
suppression of CD8+ T cell-mediated skin graft rejection.
Next, we examined the ability of rapamycin-diet and tacrolimus-
diet to induce suppression of CD8+ T cell function in the skin
using a skin graft rejection model. Transgenic skin engineered to
express OVA under the K5 promoter (i.e. from K5mOVA mice)
was rejected within ~30 days when grafted onto wild-type C57BL/
6 recipient mice as determined by graft shrinkage and necrosis
(Figure 3A; Isotype control). However, OVA-expressing skin was
not rejected when recipient mice were depleted of CD8β+ T cells
using a CD8β-depleting antibody (Figure 3A; αCD8β), thus high-
lighting the essential role played by CD8+ T cells inmediating skin
graft rejection in this model. When recipient mice were treated
before- and through-out the remainder of the experiment with
either rapamycin-diet or tacrolimus-diet, approximately 50% of
the skin grafts were not rejected (Figure 3B). In some experiments
the drug diets were stopped on Day 109, resulting in the late-stage
rejection of established skin grafts in approximately 50% (rapa-
mycin-diet) to 80% (tacrolimus-diet) of cases (data not shown).
The data indicate that the oral delivery of both rapamycin and
tacrolimus can reduce CD8+ T cell-mediated skin graft rejection.
Rapamycin concentrations in the skin are low compared
to the kidney
To examine the rapamycin and tacrolimus concentrations present
in the blood, kidney, and skin as a consequence of rapamycin-diet
and tacrolimus-diet respectively, we harvested blood, kidney, and
skin after 20 days of drug diet and analysed drug concentrations
by LC-MS/MS. As shown in Figure 4A-C, the concentration of
rapamycin and tacrolimus was significantly higher at all three
tissues sites when compared to non-drug treated controls, as
expected. The concentration of rapamycin was significantly
higher than tacrolimus in both the blood and kidney.
Unexpectedly however, this situation was reversed in the skin,
where the concentration of tacrolimus appeared significantly
higher than rapamycin. Importantly, the levels of rapamycin in
the skin were consistently around 5-15ng/gram, which might be
considered to be in the “low” range when compared to previous
reports reporting the memory T cell-promoting effects of low-
dose rapamycin (blood levels; 5–20 ng/ml 22).
Rapamycin does not prevent CD8+ effector memory T cell
infiltration into AK/SCC lesions in a model of uv-induced
SCC formation
To explore the effects of rapamycin on CD8+ memory T cells
within SCC lesions, we utilised a transgenic model in which the
E6 and E7 genes of Human Papillomavirus (HPV) type 38 are
expressed under the control of the Keratin 14 promoter.38 K14
HPV38 E6/E7-transgenic mice develop premalignant actinic ker-
atosis (AK)-like lesions and subsequently SCC following exposure
to ultraviolet (UV) light 3 times per week over the course of 20+
weeks of UV-treatment (Figure 5A). As shown in (Figure 5A)
(right panel), the emergence of tumors in this model appears as a
“field effect” rather than as distinct pathologies, and therefore AK
and SCC lesions are often interleaved and cannot be distinguished
without histological assessment. Hence, we categorized harvested
lesional skin as “AK/SCC”. We fed K14 HPV38 E6/E7 mice drug
diets for the duration of UV-treatment and noted that rapamycin
failed to significantly delay the emergence of AK/SCC lesions
(Figure 5B). Unlike no drug control and tacrolimus-treated mice,
rapamycin-treated mice did not display an increase in total CD8+
T cell abundance in AK/SCC lesions compared to fur-covered
(UV-protected) normal skin (Figure 5C; fur-covered (UV-pro-
tected) normal skin = orange triangles), UV-exposed non-lesional
skin = purple squares, and AK/SCC lesions = grey circles, as
indicated by the colour-matched circles in (A)). However, rapa-
mycin-treatment, but not tacrolimus treatment, allowed the
increased infiltration of CD8+ effector memory T cells into AK/
SCC lesions (Figure 5D). The abundance of CD8+ centralmemory
T cells appeared unchanged regardless of treatment or tissue-type
(Figure 5E), whereas CD8+ resident memory T cells appeared
reduced when normal skin was compared to UV-exposed non-
lesional skin (Figure 5F). Interestingly, this latter observation did
not hold truewhennormal skinwas compared toAK/SCC lesions,
with the caveat that sample numbers are lower in rapamycin- and
tacrolimus-treated lesional groups as some mice had to be har-
vested before the primary endpoint due to the emergence of
adverse events (particularly skin ulceration and diarrhoea), in
linewith the long-term use of these drugs. These data demonstrate
that rapamycin does not prevent CD8+ effector memory T cell
infiltration into SCC lesions.
Rapamycin promotes central- and effector memory CD8+
T -cell differentiation and function in response to new
antigen-challenges in the skin
Due to the known profoundly immunosuppressive effects of
UV-treatment on effector and memory CD8+ T cell function
and development,44 it was not possible to make functional com-
parisons of CD8+ T cell populations in the skin of drug-treated
mice using the K14 HPV38 E6/E7 model. Therefore, we exam-
ined memory CD8+ T cell function in drug-treated mice using
skin contact hypersensitivity (CHS) responses (Figure 6A). In a
short-term CHS model designed to look at acute CD8+ T cell
function, drug diets were commenced on day −15 and main-
tained throughout the experiment. Mice were sensitized with
OVA on day 0, and challenged with OVA in the ear skin on day
5 (Fig. 6Ai). 48 hours later both rapamycin and tacrolimus
induced the suppression of skin swelling in response to antigen
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Figure 2. Drug diets lead to suppression of CD8+ T cell proliferation in skin-draining lymph nodes. CFSE-labelled CD45.1+ OT-I CD8+ T cells were adoptively
transferred into C57BL/6 recipients pre-treated with either drug diet or daily drug injection. Treatments were maintained for the duration of the experiment. Inguinal
lymph nodes were harvested 72 hours following the injection of OVA or BSA control protein into the skin, and assessed for CD45.1+ CD8+ T cell proliferation. (A)
Rapamycin diet vs. daily injection. (B) Tacrolimus diet vs. daily injection. (C) and (D) Respective comparison of rapamycin and tacrolimus concentrations in the blood
the day prior to T cell transfer. Graphs show a representative experiment from 3 independent experiments with similar results; Mean ± SEM from 3–4 mice. RAPA-inj;
Rapamycin injection (2mg/kg). TAC-inj; Tacrolimus injection (10mg/kg). (E) Assessment of the effects of drug diets on TCRVα2+ OT-II CD4+ T cell proliferation in the
inguinal lymph nodes. One experiment, n = 6/group. (A-E) One-way ANOVA with post-hoc Tukey’s multiple comparisons test. ns; not significant; OVA: Ovalbumin;
BSA: Bovine Serum Albumin.
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Figure 4. Rapamycin concentration in the skin is low compared to the kidney following the establishment of clinically-relevant blood concentration
profiles. C57BL/6 mice were fed with control, rapamycin- or tacrolimus diet for 20 days before harvest of (A) Blood, (B) Kidney, and (C) Skin. Samples were then
assayed for drug concentration by LC-MS/MS. Low level drug concentrations seen in the skin of normal diet controls can be attributed to background measurements
observed during the HPLC elution process as a consequence of high levels of matrix contaminants. Data shown are combined from 4 independent experiments,
n = 12–20, bars represent mean. (A-C) One-way ANOVA with post-hoc Tukey’s multiple comparisons test. RAPA; Rapamycin diet. TAC; Tacrolimus diet. One data
point/animal.
Figure 3. Suppression of CD8+ T cell-mediated skin graft rejection. (A) Rejection of K5mOVA-expressing skin grafts is prevented in mice depleted of CD8 T cells.
Data shown are combined from 3 independent experiments (n = 8–10). Log-rank (Mantel-Cox) test p value = p < 0.0001. (B) K5mOVA ear skin graft rejection in
C57BL/6 recipient mice pre-treated with rapamycin- or tacrolimus diet for 7–14 days prior to surgery. Treatments were maintained for the duration of the
experiment, and skin graft survival monitored. Data shown are combined from 6 independent experiments (n = 10–18). Log-rank (Mantel-Cox) test p
value = p < 0.0001. Results then displayed as significant (sig.) or not significant (ns) after Bonferroni-corrected multiple comparison test. Bonferroni-corrected
threshold = 0.016, K = 3.
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challenge (Figure 6B; left panel). Differences between drug-trea-
ted and non-treated mice were lost following anti-CD8β anti-
body treatment however (Figure 6B; right panel), indicating a
key role for CD8+ T cells in this model.
In a long-termCHSmodel designed to look atmemoryCD8+T
cell function, drug diets were again commenced on day −15 and
maintained throughout the experiment.Mice were sensitized with
OVAon day 0, and challengedwithOVA in the ear skin on day 45
(Fig. 6Aii). 48 hours after OVA challenge mice treated with rapa-
mycin showed a significantly increased swelling response com-
pared to tacrolimus-treated or non-drug treated mice (Figure 6C;
left panel). Interestingly, these responseswere still higher following
CD8+ T cell depletion (Figure 6C; right panel). This enhancement
of memory CD8+ T cell function would therefore appear to be a
beneficial effect of rapamycin. In a similar long-term CHS model,
mice were sensitized with OVA on day 0 and challenged with
OVA on day 45, but drug diets were not commenced until day 33
(Figure 6Aiii). In this model the beneficial effects of rapamycin
were lost (Figure 6D; left panel, CD8+T cell depletion; right panel),
underlying the importance of the presence of rapamycin during
OVA sensitization for the enhancement of memory CD8+ T cell
function.
Quantitation of absolute numbers of effector and central mem-
ory CD8+ T cells in the ear skin of mice in (Figure 6C) (i.e. drugs
given before OVA sensitization) showed that rapamycin treat-
ment, but not tacrolimus treatment, significantly increased both
effector and central memory CD8+ T cell abundance at the site of
OVA challenge (Figures 6E and 6F respectively. Our attempt to
measure the antigen-specific production of intracellular IFN-γ
and TNFα in these cells was unsuccessful (Supplementary
Figure 5. Rapamycin does not prevent the infiltration of effector memory CD8+ T cells into AK/SCC lesions. (A) 20+ weeks of UV treatment induces AK/SCC
lesion formation in HPV38 E6E7 mice. Colored circles indicate sites of tissue harvest analyzed in (C-F). (B) Rate of AK/SCC lesion formation in mice treated with
rapamycin or tacrolimus for the duration UV treatment. (C) CD45+CD8β+ Total, (D) CD45+CD8β+CD69−CD103−CD44+CD62L− Effector Memory, (E)
CD45+CD8β+CD69−CD103−CD44+CD62L+ Central Memory, and (F) CD45+CD8β+CD69+CD103+ Resident Memory CD8+ T cell abundance in fur-covered (UV-protected)
normal skin (orange triangles), UV-exposed non-lesional skin (purple squares) and lesional skin (AK/SCC, grey circles) as indicated in (A). (B) Data pooled from 3
independent experiments, n = 6–10, differences not significant (Log-rank (Mantel-Cox) test p value = p = 0.1770). (C-F) Data pooled from 3 independent experiments,
n = 4–9, two-way ANOVA with post-hoc Tukey’s multiple comparisons test. One data point/animal.
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Figure 6. A clinically-relevant rapamycin dose promotes memory CD8+ T -cell differentiation and function in response to new antigen-challenges in the
skin. (A) Experimental timelines: i) Short-term CHS setup as in B; ii) Memory recall CHS – drugs before sensitisation as in C, E, F, and G; Memory recall CHS – drugs
after sensitisation as in D, H, I, and J. (B) Short-term CHS response, (C) Memory CHS response where drug diets are administered 15 days before OVA-sensitisation,
and (D) Memory CHS response where drug diets are administered 33 days after OVA-sensitisation. (left panel) Change in ear thickness in OVA-sensitised mice in
response to i.d. OVA challenge into the ear skin. (right panel) Effects of systemic CD8+ T cell depletion prior to antigen challenge. (B-D) ●; No drug.■; Rapamycin. ▲;
Tacrolimus. Dashed line in right-hand panels = CD8β depletion. One-way ANOVA with post-hoc Tukey’s multiple comparisons test on Day 2 shown. (B) Data are
combined from 2 independent experiments, n = 6. (C) and (D) Data are combined from 2 independent experiments, n = 8, mean ± SEM shown. (E), (F), and (G)
Absolute counts of CD45+TCRβ+CD8α+CD69−CD103−CD44+CD62L− effector memory, CD45+TCRβ+CD8α+CD69−CD103−CD44+CD62L+ central memory, and
CD45+TCRβ+CD8α+CD69+CD103+ resident memory CD8+ T cells respectively in the ears of mice on Day 55 as in (C). (H), (I), and (J) Absolute counts of effector
memory, central memory, and resident memory CD8+ T cells respectively in the ears of mice on Day 55 as in (D). (E-J) CD8β-depletion groups (open symbols)
indicated on graph. (E-G) and (H-J) Data represent one independent experiment from 3 independent experiments with similar results, n = 6, one data point/animal.
One-way ANOVA with post-hoc Tukey’s multiple comparisons test. ns; not significant. SD: Start Drugs; S-OVA: Sensitisation with OVA; C-OVA: Challenge with OVA; D:
Day. Once initiated, mice remained on drug diets for the duration of these experiments.
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Figure 3). Conversely, tacrolimus treatment but not rapamycin
treatment led to a significant increase in the abundance of resident
memory CD8+ T cells (Figure 6G). Notably, central memory
CD8+ T cells were detectable in the ear skin of some rapamycin-
treated mice treated with anti-CD8β antibody (Figure 6F), per-
haps explaining the resilience of the ear-thickening response in
rapamycin treated mice in Figure 6C.
When absolute numbers of effector and central memory CD8+
T cells were quantitated from the ear skin of mice in Figure 6D
(i.e. drugs given after OVA sensitization), the effects of rapamycin
treatment on increasing effector and central memory CD8+ T cell
abundance were lost (Figures 6H and 6I respectively). However,
the effects of tacrolimus on increasing the abundance of resident
memory CD8+ T cells were maintained (Figure 6J), suggesting
that tacrolimus treatment may increase the abundance of resident
memory CD8+ T cells in the skin in an antigen-independent
manner. Together, these data indicate that clinically-relevant
doses of rapamycin present during antigen-sensitization promote
memory CD8+ T cell function in the skin, with a corresponding
increase in the abundance of effector and central, but not resident,
memory CD8+ T cells at this site.
High dose rapamycin does not promote an increase in
central- and effector memory CD8+ T cell abundance but
does lead to increased CHS recall responsiveness
To define whether the increased swelling response observed in the
long-termCHSmodel following rapamycin treatment (Figure 6C;
6E-G) was the result of the increased absolute numbers of effector
and central memory CD8+ T cells in the skin, we repeated the
experiment outlined in (Figure 6Aii) with the inclusion of the
injection of a high dose of rapamycin. As a prelude to this experi-
ment we initially confirmed that the daily i.p. injection of 8mg/kg
of rapamycin would lead to an increased concentration of rapa-
mycin in the skin when compared to the levels induced by the
rapamycin-diet.We harvested skin after 10 days of rapamycin diet
or daily rapamycin injection and analysed the rapamycin concen-
tration by LC-MS/MS. As shown in (Figure 7A), the daily i.p.
injection of 8mg/kg of rapamycin corresponded to an approxi-
mately 10-fold increase in skin rapamycin concentration. Next, we
used the expression of the iron transferrin receptor CD71 on
CD8+ T-cells in the skin to determine whether the concentrations
of rapamycin present in the skin led to a lower a lower inhibition
of the mTOR pathway compared with the spleen or inguinal
lymph nodes (Figure 7B). Visually, the expression of CD71
appeared higher in the skin than the spleen or lymph nodes,
suggesting that indeed the mTOR pathway in CD8+ T-cells was
more active in the skin than the spleen or lymph nodes, although
the differences were not statistically significant. Unexpectedly
however, both rapamycin delivery methods appeared not to affect
CD71 expression by CD8+ T-cells in the skin when compared to
control mice (Figure 7B). Since CD71 expression is reported to be
up-regulated on activated T cells,45 the data suggest that CD8+
T-cells might be activate in the skin following both “low dose”
(rapamycin-diet) and “high dose” (daily 8mg/kg injection) rapa-
mycin administration.
We repeated the long-term CHS model (as in Figure 6Aii),
in which rapamycin was present before antigen sensitisation
and maintained throughout the experiment, to determine the
effects of high rapamycin dose treatment. High dose rapamy-
cin treatment, unlike rapamycin-diet, did not increase the
absolute numbers of effector and central memory CD8+ T
cells in the ear skin when compared with the no drug controls
(Figures 7C and 7D respectively). Notably, while rapamycin-
diet resulted in a significantly greater abundance of effector
memory CD8+ T cells when compared with high dose rapa-
mycin (Figure 7C), there was not a significant difference in
the abundance of central memory CD8+ T cells between these
two treatments (Figure 7D). Surprisingly, high dose rapamy-
cin treatment induced a similar degree of increased skin
swelling in response to antigen challenge as that induced by
rapamycin-diet (Figure 7E), suggesting that both drug treat-
ments improved the recall response to OVA. In contrast to
rapamycin-diet, however, the surface expression of CD71 on
CD8+ T cells in the ear skin also increased following high dose
rapamycin treatment (Figure 7F). A closer examination of
memory marker expression confirmed that this increase was
not due to an increase in expression by effector memory
CD8+ T cells but rather was due to an increase in expression
by central memory CD8+ T cells (Figures 7G and 7H respec-
tively), suggesting that central memory CD8+ T cells were
highly activated in the skin of mice receiving high dose
rapamycin. Together, these data indicate that high dose rapa-
mycin treatment does not induce the differentiation of effec-
tor or central memory CD8+ T cells in the skin, but does
increase CHS responses. This suggests that the increased CHS
responses observed following clinically-relevant doses of rapa-
mycin are not simply a factor of the generation of a greater
abundance of effector- or central memory CD8+ T cells.
Discussion
The measurement of whole blood concentrations of rapamycin
and tacrolimus upon initiation and maintenance of drug therapy
is the standard clinical practise in patients with solid organ trans-
plants. The target therapeutic level for these drugs varies depend-
ing on individual circumstances; however it is generally
considered that an average concentration over a 24-hour period
of 10 – 30 ng/ml for rapamycin,42 and trough concentration of 5 –
20 ng/ml for tacrolimus 43 is needed for effective immunosuppres-
sion in the clinic. We have recently confirmed that rapamycin
treatment, but not calcineurin inhibitor treatment, leads to sig-
nificant increases in the abundance of CD8+ memory T cells in
sun-exposed skin as compared to non-sun exposed skin in kidney
transplant patients.27 However, to circumvent the challenges of
performing functional assessments of memory CD8+ T cells in
patient skin, we established drug-incorporated diets, which when
fed to mice, resulted in the establishment of clinically-relevant
rapamycin and tacrolimus concentrations in the blood. The
advantage of this methodology is that mice can be administered
drugs orally over long periods of time, as they are in humans,
without the need for daily (or twice-daily) injections. The caveat
however, is that the level of drugs the mice receive is directly
proportional to the amount of food they choose to eat.
Nevertheless, despite a slight reduction in overall weight gain
(Supplementary Figure 1E), we observed that this method of
drug administration was well-tolerated in the mice, and resulted
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in consistent levels of rapamycin being detected in the skin
(Figure 4C).
We observed that despite the levels of rapamycin in the blood
being higher than for tacrolimus, the accumulation of rapamycin
in the skin was much lower. This may explain reports in a
previous study describing that the levels of rapamycin needed to
delay the rejection of skin allografts are 15–30 fold higher than
those needed to completely prevent cardiac allograft rejection. By
contrast, equivalent doses of cyclosporine A (belonging to the
same class of drugs as tacrolimus) showed a similar efficacy
regarding the engraftment of these two tissue types.46
Importantly, the levels of rapamycin in the skin (around 8.2 ng
per gram on average) appeared to increase the quality and quan-
tity of OVA-specific memory CD8+ T cells in the skin in a model
of CHS – providing that rapamycin was present during antigen
sensitization. This is in keeping with previous reports of
enhancements in the quality and quantity of virus-specific mem-
ory CD8+ T cells in the lymphoid organs of mice and blood of
non-human primates injected i.p. and i.m. (respectively) with
rapamycin.22 Thus, our findings may suggest that patients
switched to mTOR inhibitor regimens may well benefit from
enhanced CD8+ memory T cell function to new antigen-chal-
lenges in their skin, such as those induced through new UV-
induced mutations. We speculated that these beneficial effects in
the skin could be lost when the doses of rapamycin that patients
receive are too high. Surprisingly, our mouse data suggest that
while higher doses of rapamycinmay indeed prevent the increases
in CD8+ memory T cell differentiation seen with lower doses of
rapamycin, the improved recall response to OVA in a long-term
CHS model was maintained. Furthermore, CD71 expression
levels were increased on central memory CD8+ T cells in the
skin of mice receiving higher doses of rapamycin suggesting
Figure 7. A high rapamycin dose does not promote memory CD8+ T -cell differentiation but does enhance long-term CHS responses to OVA. (A-B) C57BL/6
mice were fed with control or rapamycin diet, or injected daily with high dose (8mg/kg) rapamycin for 10 days before tissue harvest. (A) Rapamycin concentration in
the skin measured by LC-MS/MS. (B) CD71 surface expression on CD8+ T-cells in the spleen, inguinal lymph nodes (iLN), and skin was analysed by FACS. Differences
not significant (two-way ANOVA with Dunnett’s multiple comparisons test). (C-H) Memory recall CHS – rapamycin before sensitisation as in Fig. 6Aii. C57BL/6 mice
were fed with control or rapamycin diet, or injected daily with high dose (8mg/kg) rapamycin throughout the experiment. (C) Absolute counts of
CD45+TCRβ+CD8α+CD69−CD103−CD44+CD62L− effector memory, and (D) CD45+TCRβ+CD8α+CD69−CD103−CD44+CD62L+ central memory CD8+ T cells in the ears
of mice on Day 55. (E) Memory CHS response. ●; No drug.■; Rapamycin diet. □; Daily rapamycin injection (8mg/kg). One-way ANOVA with post-hoc Tukey’s multiple
comparisons test on Day 2 shown. (F-H) CD71 surface expression on (F) total CD8+ T-cells, (G) effector memory CD8+ T-cells, and (H) central memory CD8+ T-cells in
the skin on day 55. (G) and (H), markers as in (C) and (D) respectively. (A), (C), (D), (F-H) One-way ANOVA with post-hoc Tukey’s multiple comparisons test. ns; not
significant. (A), (C), (D) One data point/animal. Data are derived from one experiment.
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enhanced functionality of these cells. However, the link between
the prolonged use of rapamycin, the dose of rapamycin used, and
the consequent effects on CD8+ T-cell functionality remains
poorly-defined, yet warrants further investigation.
Our data further suggest that the effects of rapamycin on
“memory” cells in the skin are restricted to effector and
central, but not resident, memory subsets. Elsewhere, rapa-
mycin has been reported to inhibit the formation of resident
memory CD8+ T cells in the intestinal and vaginal mucosa, by
inhibiting the formation of resident mucosal memory CD8+ T
cell precursors.47 These findings may be explained, at least in
part, by the observation that blockade of the mTOR pathway
promotes the expression of the T-box transcription factor
eomesodermin,25 but near-extinguishment of eomesodermin
is necessary for resident memory T cell development.48
We show here that clinically-relevant doses of rapamycin
do not appear to impact on the abundance of DC in the
epidermis or dermis, at least over the short-term. Similar
observations regarding the abundance of Langerhans cells
have been made in patient SCC lesions taken before and
after conversion from calcineurin inhibitors to sirolimus.49
However, a recent study in mice has shown that the home-
ostasis of Langerhans cells critically depends on mTORC1,
which is blocked by rapamycin, and furthermore that the
ablation of mTORC1 activity leads to the progressive loss of
Langerhans cells in the skin over time due to enhanced
migration to the skin draining lymph nodes.50 Therefore,
future examination of antigen presenting cell types in the
skin following the long term use of rapamycin in the con-
text of our- or similar- models appears both timely and
appropriate if we are to fully understand the impact of
long-term rapamycin use on residual immune function in
patient skin.
The impact that rapamycin has on memory T cell differ-
entiation and function within cutaneous SCC lesions in the
clinic, and the role that these cells subsequently have in the
prevention of de novo lesion formation and the regression
of premalignant lesions, is currently unclear. In mice how-
ever, low dose mTOR inhibition has been shown to produce
little interference with the production of effector molecules
such as IFN-γ, perforin, or granzyme B.26 Furthermore, the
combination of (rapamycin-independent) IFN-γ with rapa-
mycin has recently been shown to promote γδ TCRmid T
cell-mediated prevention of tumour formation in a DMBA/
TPA skin carcinogenesis model.51 The K14 HPV38 E6/E7
mouse model is the only UV-induced mouse tumor model
that we are aware of that consistently and specifically pro-
duces SCC lesions as oppose to papillomas or mixed skin
tumour types. Using this model we show here that unlike
tacrolimus-treatment, rapamycin treatment allows the
migration of CD8+ effector memory T cells into AK/SCC
lesions induced by UV-treatment. However, rapamycin-
treatment could not prevent lesion formation in UV-treated
mice in the first instance. This observation agrees with a
previous study utilizing UV-treatment of SKH-1 hairless
mice, in which rapamycin reduced the numbers and area
of papilloma tumours but could not prevent tumour
emergence.52 Whether or not rapamycin treatment could
allow T cells to prevent SCC emergence is difficult to define
in these models due to the requirement that UV-treatment
be used for SCC induction, and the associated immunosup-
pressive nature of UV-treatment on memory T cell function
and development.44 Further complicating the issue is the
fact that SCC are highly immunogenic tumours,53 and
transplantable SCC models often do not establish in
immune competent mice.
Taken together, we have demonstrated that unlike clini-
cally-relevant concentrations of tacrolimus in the blood, clini-
cally-relevant concentrations of rapamycin in the blood
correspond to a relatively “low dose” drug environment in
the skin. This environment allowed the infiltration of CD8+
effector memory T cells into UV-induced SCC lesions, and
enhanced the number and function of antigen-specific CD8+
effector and central memory T cells in the skin following new
antigenic challenge. Thus, our findings suggest that patients
switched to mTOR inhibitor treatment regimens from calci-
neurin inhibitor treatment regimens may well benefit from
residual CD8+ T cell function in their skin. Our results advo-
cate further study into the contribution that immune mechan-
isms may play in the reduced risk of SCC development
associated with rapamycin treatment.
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